Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase.
about
Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain sheddingA comprehensive manually curated reaction map of RANKL/RANK-signaling pathwayA review of denosumab for the treatment of osteoporosisRANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy ReceptorCatalytic properties of ADAM19Catalytic activity of human ADAM33Autolytic processing at Glu586-Ser587 within the cysteine-rich domain of human adamalysin 19/disintegrin-metalloproteinase 19 is necessary for its proteolytic activityThe enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPsMutation of a conserved hydrophobic patch prevents incorporation of ZP3 into the zona pellucida surrounding mouse eggsEssential role for ADAM19 in cardiovascular morphogenesisMembrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substratesIdentification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding.Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathwayShedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.Interleukin-1 stimulates ADAM17 through a mechanism independent of its cytoplasmic domain or phosphorylation at threonine 735Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myelomaMatrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.Molecular and cellular mechanisms of ectodomain sheddingCirculating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.ADAM function in embryogenesisOsteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.New regulation mechanisms of osteoclast differentiation.Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs.Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha.Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway.Tumor necrosis factor-alpha-converting enzyme (TACE) levels in periodontal diseases.Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch.Regulation of ADAM12 cell-surface expression by protein kinase C epsilon.An assessment of ADAMs in bone cells: absence of TACE activity prevents osteoclast recruitment and the formation of the marrow cavity in developing long bones.MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17.Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding.Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide.Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding.Processing of the human transferrin receptor at distinct positions within the stalk region by neutrophil elastase and cathepsin G.Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme.ADAM-17-independent shedding of L-selectin.
P2860
Q24305047-E6FEF5D8-A9F8-4DB0-87B7-8CB10B263454Q24599024-804B78C0-CACB-4B8E-AFBC-3C8DDDD05FC0Q27005894-BA058F32-DEC6-42CA-B8FE-E1B628AED375Q27674275-3E497DDD-EE7C-4936-999D-55EDF8FB0FC1Q28189426-A5C69C7A-ABEB-4A8F-949F-8F69DB3D9BD0Q28191609-04E5E58F-E828-4405-A1E6-3A0A5202C7FDQ28209976-02C7A06B-D428-4342-9083-0ABA4771522EQ28215674-043F36EC-E8F5-437D-B966-D0B77BFE69D3Q28585903-5681BF14-6E57-4B2B-A15C-4511971E5662Q28594617-94D31084-A134-48C9-A71A-2797F33A0ECEQ33202468-F3889753-6803-4CBB-A61C-B4A7507D8EEEQ33225474-35B4EB3A-EDF0-451D-AB0F-A978D5839AF9Q33885108-14E0D5CA-D490-48D7-9937-D4115FDA8124Q33958982-54A3768F-0DF8-4BF0-9C6A-101D77BBBCB5Q34181792-DC4FAE18-E37C-4F88-A8E2-65B3C7F28551Q34404651-05D20229-B849-419F-98E3-AF3FA84F4FBFQ35184303-68185069-141F-4355-9CB2-56A0886AE44EQ35855547-592C5F65-EA1C-40F2-8451-76B3C8F90CA4Q36210626-CA50EE78-9974-493F-9122-34238EA49BC2Q36641523-0D1E601A-2A87-4C1A-9751-8F4589CBC450Q36891815-7DF03FBF-AA9D-4D2E-A28E-E008B77EC45DQ37303309-B4179D37-52F2-428B-9787-8211E0682070Q37350475-014A5238-BBC9-47B9-AF77-29E8928891C5Q37447482-B8760F6B-1308-48BD-ACFD-A6F97FBBF073Q37987556-85E9F998-2845-46D2-BAAE-D254BBE92752Q38722186-D944DE95-AB40-4ED1-B3C5-0D7DF17B5595Q39658973-FA2E8905-821F-4255-BF7F-513A93B31D9EQ39797126-12CACB38-210B-4334-8D89-33BBCC1D475CQ39943187-54BBBA20-8473-4D80-96DF-397D0409EA06Q40120823-B4B74A9F-8E7F-4404-887F-CECE7D7DF11DQ40450148-FAE9554E-2AEB-4C24-8E67-6284332D08A8Q40516107-1FF9DC5E-8EC5-4232-8935-D1BAE964F340Q40554373-983A076B-F603-4031-ACC2-FA6A9BB3A460Q40558602-14038211-7135-4FAD-93C5-C5932A4100CAQ40652249-1784434B-4E14-4C5C-99A5-C7DFA110D1D1Q40666006-D38F85BA-41E2-4320-9931-00D615B9830BQ40688718-2327AEB8-2419-4034-902D-ECDBB39EC852Q40705037-D9BAD9E4-A469-462F-8BB1-053A2AF6FFCBQ40774834-A041EC35-DE00-49E1-BF51-E10C2E785808Q42446882-B75DF1C6-CCFB-44A7-BB1B-DF655207E347
P2860
Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@en
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@nl
type
label
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@en
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@nl
prefLabel
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@en
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@nl
P2093
P2860
P356
P1476
Biochemical and pharmacologica ...... rosis factor alpha convertase.
@en
P2093
P2860
P304
14665-14674
P356
10.1074/JBC.M010741200
P407
P577
2001-01-30T00:00:00Z